Global Cervical Cancer Treatment Market, By Type (Squamous Cell Carcinoma, Adenocarcinoma), Product (Prevention, Treatment), Treatment (Surgery, Radiation, Chemotherapy, Immunotherapy), Route of Administration (Oral, Parenteral, Others), End-Users (Hospitals, Homecare, Specialty Clinics, Others), Distribution Channel (Hospital Pharmacy, Online Pharmacy, Retail Pharmacy) – Industry Trends and Forecast to 2030.
Cervical Cancer Treatment Market Analysis and Size
Cervical cancer has a mortality rate of approximately 50%, which can be minimized by diagnosis and prevention. Since the disease progression is usually slow, precancerous changes provide possibilities for prevention and treatment. Most cases are presented at later stages of disease progression because of lack of awareness or inaccessibility to diagnostic facilities. Human Papillomavirus (HPV) is a major causative factor for cervical cancer, normally acquired through sexual transmission. There are more than 100 strains of HPV, out of which 13 are high-risk or cancerous.
Data Bridge Market Research analyses a growth rate in the cervical cancer treatment market in the forecast period 2023-2030. The expected CAGR of mesothelioma treatment market is tend to be around 5.5% in the mentioned forecast period. The market was valued at USD 8.23 million in 2022, and it would grow upto USD 12.63 million by 2030. In addition to the market insights such as market value, growth rate, market segments, geographical coverage, market players, and market scenario, the market report curated by the Data Bridge Market Research team also includes in-depth expert analysis, patient epidemiology, pipeline analysis, pricing analysis, and regulatory framework.
Cervical Cancer Treatment Market Scope and Segmentation
|
Report Metric
|
Details
|
|
Forecast Period
|
2023 to 2030
|
|
Base Year
|
2022
|
|
Historic Years
|
2021 (Customizable to 2015 - 2020)
|
|
Quantitative Units
|
Revenue in USD Million, Volumes in Units, Pricing in USD
|
|
Segments Covered
|
Type (Squamous Cell Carcinoma, Adenocarcinoma), Product (Prevention, Treatment), Treatment (Surgery, Radiation, Chemotherapy, Immunotherapy), Route of Administration (Oral, Parenteral, Others), End-Users (Hospitals, Homecare, Specialty Clinics, Others), Distribution Channel (Hospital Pharmacy, Online Pharmacy, Retail Pharmacy)
|
|
Countries Covered
|
U.S., Canada and Mexico in North America, Germany, France, U.K., Netherlands, Switzerland, Belgium, Russia, Italy, Spain, Turkey, Rest of Europe in Europe, China, Japan, India, South Korea, Singapore, Malaysia, Australia, Thailand, Indonesia, Philippines, Rest of Asia-Pacific (APAC) in the Asia-Pacific (APAC), Saudi Arabia, U.A.E, South Africa, Egypt, Israel, Rest of Middle East and Africa (MEA) as a part of Middle East and Africa (MEA), Brazil, Argentina and Rest of South America as part of South America
|
|
Market Players Covered
|
Johnson & Johnson Private Limited (U.S.), Mylan N.V. (U.S.), Sun Pharmaceutical Industries Limited(Mumbai), Sanofi S.A.( France), CLOVIS ONCOLOGY (U.S.), Bayer AG (Germany), Lilly (U.S.), Merck & Co., Inc. (U.S.), GSK plc (U.K.), Novartis AG (Switzerland), AbbVie Inc. (U.S.), Vivesto AB (Sweden), Alnylam Pharmaceuticals, Inc (U.S.), Biocon (India), Genentech, Inc (U.S.), Hetero (India)
|
|
Market Opportunities
|
|
Market Definition
Cervical cancer is the cancer that appears in the form of tumour formation in cervix cells. Numerous strains of human papillomavirus (HPV), sexually transmitted agent that can cause infection are responsible for generating the cervical cancer. Cervical cancer initiates when healthy cells of the cervix develop changes (mutations) in their DNAs.
Global Cervical Cancer Treatment Market Dynamics
Drivers
- Availability of Vaccines
There has been a wide availability of vaccines that have been launched to improve the patient’s recovery process. For instance, Gardasil led the preventive vaccine segment in 2017, supported by strong commercial sales globally. In addition, the FDA approved Gardasil 9, an improvised, nonavalent version of Gardasil, in 2015. This label expansion gave Gardasil and Gardasil 9 a distinct clinical advantage over Cervarix. Thus, this factor enhances the market growth.
- Increasing Demand for Targeted Therapy
The increasing demand for targeted therapy showed many advantages as it interferes with specific proteins involved in tumorigenesis, focusing on specific molecular changes that stop the growth of numerous cancers. Several significant factors influenced the growth of gynecology cancer, including the fewer adverse effects of the therapy and the availability of several targeted therapeutics. This boosts the market growth.
Opportunities
- Growing Adoption of Biologics
There has been a growing adoption of biologics, creating many market growth opportunities. For instance, Avastin (bevacizumab) was approved for the treatment of cervical cancer in 2014. Avastin was approved in Europe and Japan in 2015 and 2016, respectively. Besides this, the FDA approved Keytruda in 2018. Although generic products continue to capture major market share, the arrival of biologics and other targeted therapies show a substantial shift in this therapeutic space through the forecast period.
- Increasing Demand for Online Pharmacies
Online pharmacies segment is projected to be the fastest-growing distribution channel segment. This growth can be due to its user-friendly interfaces and convenience in terms of access, prices, and delivery. In addition, they offer numerous discounts on purchasing a certain amount or bundle pricing for cancer products.
Restraints/Challenges
- Side Effects of Chemotherapy
There are various side effects that are associated with chemotherapy. Effects such as nausea and vomiting, hair loss, and mouth sores decrease market growth.
- High Cost
The huge expenditure associated with these agents hamper the market growth. The high treatment costs and the prices of several medications including biologics hinder the market growth.
This cervical cancer treatment market report provides details of new recent developments, trade regulations, import-export analysis, production analysis, value chain optimization, market share, impact of domestic and localized market players, analyses opportunities in terms of emerging revenue pockets, changes in market regulations, strategic market growth analysis, market size, category market growths, application niches and dominance, product approvals, product launches, geographic expansions, technological innovations in the market. To gain more info on the cervical cancer treatment market contact Data Bridge Market Research for an Analyst Brief, our team will help you take an informed market decision to achieve market growth.
Global Cervical Cancer Treatment Market Scope
The cervical cancer treatment market is segmented on the basis of type, product, treatment type, route of administration, distribution channel and end-user. The growth amongst these segments will help you analyze meagre growth segments in the industries and provide the users with a valuable market overview and market insights to help them make strategic decisions for identifying core market applications.
Type
- Squamous Cell Carcinoma
- Adenocarcinoma
Product
- Prevention
- Gardasil/Gardasil9
- Cervarix
- Treatment
- Avastin
- Keytruda
- Generics
- Others
Treatment Type
- Surgery
- Radiation
- Chemotherapy
- Immunotherapy
Route of Administration
- Oral
- Parenteral
- Others
End User
- Hospitals
- Homecare
- Specialty Clinics
- Others
Distribution Channel
- Hospital Pharmacy
- Online Pharmacy
- Retail Pharmacy
Cervical Cancer Treatment Market Regional Analysis/Insights
The cervical cancer treatment market is analyzed and market size insights and trends are provided by type, product, treatment type, route of administration, distribution channel and end-user as referenced above.
The major countries covered in the cervical cancer treatment market report are the U.S., Canada and Mexico in North America, Germany, France, U.K., Netherlands, Switzerland, Belgium, Russia, Italy, Spain, Turkey, Rest of Europe in Europe, China, Japan, India, South Korea, Singapore, Malaysia, Australia, Thailand, Indonesia, Philippines, Rest of Asia-Pacific (APAC) in the Asia-Pacific (APAC), Saudi Arabia, U.A.E, South Africa, Egypt, Israel, Rest of Middle East and Africa (MEA) as a part of Middle East and Africa (MEA), Brazil, Argentina and Rest of South America as part of South America.
Asia-Pacific has been witnessing a positive growth for cervical cancer treatment market throughout the forecasted period due to increased demand of cost-effective treatment solutions.
North America dominates the market due to the increased technological developments of the product, high research and development, healthcare expenditure, and skilled professionals.
The country section of the report also provides individual market impacting factors and changes in regulation in the market domestically that impacts the current and future trends of the market. Also, the presence and availability of global brands and their challenges faced due to large or scarce competition from local and domestic brands, impact of domestic tariffs and trade routes are considered while providing forecast analysis of the country data.
Competitive Landscape and Global Cervical Cancer Treatment Market Share Analysis
The cervical cancer treatment market competitive landscape provides details by competitor. Details included are company overview, company financials, revenue generated, market potential, investment in research and development, new market initiatives, global presence, production sites and facilities, production capacities, company strengths and weaknesses, product launch, product width and breadth, application dominance. The above data points provided are only related to the companies' focus related to glbal cervical cancer treatment market.
Key players operating in the cervical cancer treatment market include:
- Johnson & Johnson Private Limited (U.S.)
- Mylan N.V. (U.S.)
- Sun Pharmaceutical Industries Limited(India)
- Sanofi France)
- CLOVIS ONCOLOGY (U.S.)
- Bayer AG (Germany)
- Lilly (U.S.)
- Merck & Co., Inc. (U.S.)
- GSK plc (U.K.)
- Novartis AG (Switzerland)
- AbbVie Inc. (U.S.)
- Vivesto AB (Sweden)
- Alnylam Pharmaceuticals, Inc (U.S.)
- Biocon (India)
- Genentech, Inc (U.S.)
- Hetero (India)
SKU-